Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa with or without IV Iron in Anemic Cancer Patients
NCT00135317Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: Proportion of subjects achieving a hematopoietic response. Started Nov 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00135317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135317.